GlassScriptPhysician profile
Ashley Steinis
NPI 1356015051
$1,373.61
in general payments reported to CMS, 2019-2025
20 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.52 · 2023: $146 · 2024: $691 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $42.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.48 |
| Education | $42.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $377.83 | 2023-2024 | Farxiga, Fasenra, Brilinta |
| Novartis Pharmaceuticals Corporation | $192.79 | 2024-2025 | |
| Amgen INC. | $134.03 | 2024-2025 | Uplizna, Aranesp, Tavneos |
| Novo Nordisk INC | $75.50 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Baxter Healthcare | $70.82 | 2023-2025 | Renal - Pd |
| Travere Therapeutics, INC. | $64.43 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.07 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $54.83 | 2024-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.77 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $39.53 | 2024-2025 | Rayaldee |
| Cycle Pharmaceuticals INC | $35.80 | 2025 | Venxxiva |
| Pfizer INC. | $35.34 | 2024-2025 | |
| Vifor Pharma, INC. | $29.88 | 2024 | Veltassa |
| Sanofi-Aventis U.S. LLC | $25.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2025 | Keveyis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $24.03 | 2024 | Lupkynis |
| Calliditas Therapeutics US INC. | $21.15 | 2025 | Tarpeyo |
| Rhythm Pharmaceuticals, INC. | $19.93 | 2025 | Imcivree |
| Azurity Pharmaceuticals, INC. | $18.76 | 2023 | Horizant |
| Lilly USA, LLC | $16.32 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Steinis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.